CD19 and acute lymphoblastic leukemia: The US Food and Drug Administration (FDA) has authorized two CAR T-cell therapies targeting CD19 for treating relapsed or refractory (r/r) B-ALL (tisagenlecleucel (Kymriah) and brexucabtagene autoleucel (Tecartus)).